Multiple Myeloma

The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.

Andrzej Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the posttransplant setting.

Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.

Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.

Panelists discuss how health care providers and patients should understand that talquetamab's unique adverse effects are temporary and resolve over time, even while continuing treatment, emphasizing the drug's excellent efficacy and the importance of removing stigma around its manageable toxicity profile.

Panelists discuss how effective caregivers should join support groups, maintain detailed records of symptoms and medications, attend all appointments, stay informed about myeloma research, and serve as active advocates who can communicate with health care teams when patients cannot.

Panelists discuss how patients beginning talquetamab treatment should maintain a positive attitude, prepare thoroughly with educational materials, and understand that although initial adverse effects can be challenging, they are temporary and manageable with proper preparation and support.

Panelists discuss how patients can maintain their nutrition during talquetamab treatment by focusing on texture and food presentation when taste is impaired, using high-calorie options, and remembering that taste changes and dry mouth are temporary adverse effects that improve over time.

Patients with multiple myeloma who received palonosetron, dexamethasone, aprepitant, and olanzapine achieved a 44.1% CR rate across all study phases.

D-VRd had a 72% chance of providing superior PFS outcomes vs isatuximab plus VRd in patients with transplant-ineligible NDMM.

Treatment with anito-cel shows a predictable and manageable safety profile among those with relapsed/refractory multiple myeloma in the iMMagine-1 trial.

Panelists discuss how expectations for treatment outcomes can become more positive over time through experience with multiple therapies, staying informed about clinical trials and new treatments, and focusing on quality of life as a primary treatment goal alongside disease control.

Patients with high-risk markers may especially benefit from the addition of daratumumab to lenalidomide as maintenance therapy for NDMM.

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.

CRS, neurotoxicities, and infections are the most common AEs associated with BCMA- and GPRC5D-directed therapies in patients with multiple myeloma.

Marc S. Raab, MD, PhD, details how agents such as carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.

Panelists discuss how caregivers can navigate the initial shock of a myeloma diagnosis by seeking reliable information from trusted medical websites, connecting with local support groups, and accessing resources from organizations such as the International Myeloma Foundation (IMF), Multiple Myeloma Research Foundation (MMRF), and patient advocacy groups.

Panelists discuss how Alan Plisskin's multiple myeloma diagnosis began with severe back and hip pain, progressed through life-threatening complications, including seizures and vocal cord paralysis, and revealed extensive lytic lesions throughout his body that required immediate intensive treatment.

The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.

Recent advancements in multiple myeloma treatment highlight the efficacy of daratumumab combined with VRd, showcasing improved outcomes and tolerability.

The VGPR or better rate was 87.8% in patients treated with Isa-VRd who had transplant-ineligible newly diagnosed multiple myeloma.

No TRAEs leading to dose discontinuation, DLTs, or belantamab-related corneal events above grade 1 occurred with belantamab in multiple myeloma.

Updated findings from AURIGA support the value of adding subcutaneous daratumumab to lenalidomide maintenance in MRD-positive NDMM after transplant.

Phase 1b/2 BGB-11417-105 trial data showed low rates of high-grade infection and hematologic toxicity with sonrotoclax-based therapy in multiple myeloma.

Belantamab mafodotin plus lenalidomide and dexamethasone yielded a stringent CR of 42.9% in patients with newly diagnosed multiple myeloma.